Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Giampieri, Riccardo ^a   Salvatore, Lisa ^b   Del Prete, Michela ^a   Prochilo, Tiziana ^c   Danzeo, Marco ^a   Loretelli, Cristian ^a   Loupakis, Fotios ^b   Aprile, Giuseppe ^d   MacCaroni, Elena ^a   Andrikou, Kalliopi ^a   Bianconi, Maristella ^a   Bittoni, Alessandro ^a   Faloppi, Luca ^a   Demurtas, Laura ^e   Montironi, Rodolfo ^a   Scarpelli, Marina ^a   Falcone, Alfredo ^b   Zaniboni, Alberto ^c   Scartozzi, Mario ^e   Cascinu, Stefano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Medical Oncology   (Italy)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

^e DEPARTMENT OF RADIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBANILAMIDE DERIVATIVE; FIBROBLAST GROWTH FACTOR RECEPTOR; PYRIDINE DERIVATIVE; REGORAFENIB; VASCULOTROPIN A; VASCULOTROPIN C; VEGFA PROTEIN, HUMAN; VEGFC PROTEIN, HUMAN;

ADULT; AGED; COLORECTAL TUMOR; FEMALE; GENETICS; GENOTYPING TECHNIQUE; HUMAN; MALE; METASTASIS; MIDDLE AGED; PHARMACOGENETIC VARIANT; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; COLORECTAL NEOPLASMS; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHARMACOGENOMIC VARIANTS; PHENYLUREA COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIDINES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84964653262     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25195     Document Type: Article

References (18)

1. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 26, 303-12 (2013).
2. Li, J. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 16, 619-29 (2015).
3. Van Cutsem, E. et al. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. Ann. Oncol. 26, 118 (2015).
4. Tougeron, D. et al. REBECCA: a large cohort study of regorafenib (REG) in the real-life setting in patients (PTS) previously treated for metastatic colorectal cancer (MCRC). Ann. Oncol. 25, 205-206 (2014).
5. Giampieri, R. et al. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Crit. Rev. Oncol. Hematol. 88, 272-283 (2013).
6. Del Prete, M. et al. Panitumumab for the treatment of metastatic colorectal cancer: a review. Immunotherapy. 7, 721-38 (2015).
7. Prete, M. D. et al. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget. 6, 33982-92 (2015).
8. Sitohy, B., Nagy, J. A., Dvorak, H. F. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 72, 1909-14 (2012).
9. Scartozzi, M. et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int. J. Cancer. 135, 1247-56 (2014).
10. Scartozzi, M. et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br. J. Cancer. 108, 1126-32 (2013).
11. Pander, J., Gelderblom, H., Guchelaar, H. J. Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov. Today. 12, 1054-60 (2007).
12. Tabernero, J. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16, 499-508 (2015).
13. Masi, G. et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann. Oncol. 26, 724-30 (2015).
14. Kubicka, S. et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann. Oncol. 24, 2342-9 (2013).
15. Giampieri, R. et al. The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treat. Rev. 40, 934-41 (2014).
16. Tabernero, J. et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 16, 937-48 (2015).
17. Slattery, M. L., Lundgreen, A., Wolff, R. K. VEGFA, FLT1, KDR and colorectal cancer: assessment of disease risk, tumor molecular phenotype, and survival. Mol. Carcinog. 53, 140-50 (2014).
18. Holm, S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics. 6, 65-70 (1979).